Sridhar Vasudevan is a translational pharmacologist with a DPhil from Oxford University. His research focuses on understanding the circadian clock and developing innovative drug targets to address unmet needs in multiple disorders. His work has been published in leading journals and he has received recognition for his contributions, including the Enterprise Fellowship from the Royal Society of Edinburgh and the Oxford University Research Excellence Award. Dr. Vasudevan also teaches multiple courses in pharmacology for undergraduate (medical, biomedical) and MSc students. Dr. Vasudevan is a reviewer for multiple journals and granting agencies, and he consults for several pharmaceutical companies. He has a proven track record of translating scientific discoveries into clinical applications. Over the past decade, his lab has successfully advanced two first-in-class small molecule programs into Phase 2 clinical trials for bipolar disorder and circadian rhythm disorder. Dr. Vasudevan co-founded and oversees research at Circadian Therapeutics, an Oxford University spin-out.